Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial by Marvel, Skylar W. et al.
Submitted 15 July 2016
Accepted 15 March 2017
Published 2 May 2017
Corresponding author
Alison A. Motsinger-Reif,
alison_motsinger@ncsu.edu
Academic editor
Ryan Hernandez
Additional Information and
Declarations can be found on
page 16
DOI 10.7717/peerj.3187
Copyright
2017 Marvel et al.
Distributed under
Creative Commons CC-BY 4.0
OPEN ACCESS
Common and rare genetic markers of
lipid variation in subjects with type 2
diabetes from the ACCORD clinical trial
Skylar W. Marvel1,*, Daniel M. Rotroff1,2,*, Michael J. Wagner3, John B. Buse4,
Tammy M. Havener3, Howard L. McLeod5, Alison A. Motsinger-Reif1,2 and
The ACCORD/ACCORDion Investigators
1Bioinformatics Research Center, North Carolina State University, Raleigh, NC, United States of America
2Department of Statistics, North Carolina State University, Raleigh, NC, United States of America
3Center for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill,
Chapel Hill, NC, United States of America
4Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC,
United States of America
5Moffitt Cancer Center, Tampa, FL, United States of America
*These authors contributed equally to this work.
ABSTRACT
Background. Individuals with type 2 diabetes are at an increased risk of cardiovascular
disease. Alterations in circulating lipid levels, total cholesterol (TC), low-density
lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides (TG) are heritable
risk factors for cardiovascular disease. Here we conduct a genome-wide association
study (GWAS) of common and rare variants to investigate associations with baseline
lipid levels in 7,844 individuals with type 2 diabetes from the ACCORD clinical trial.
Methods. DNA extracted from stored blood samples from ACCORD participants were
genotyped using the Affymetrix Axiom Biobank 1 Genotyping Array. After quality
control and genotype imputation, association of common genetic variants (CV),
defined as minor allele frequency (MAF) ≥ 3%, with baseline levels of TC, LDL, HDL,
and TG was tested using a linear model. Rare variant (RV) associations (MAF < 3%)
were conducted using a suite of methods that collapse multiple RV within individual
genes.
Results.Many statistically significant CV (p< 1×10−8) replicate findings in largemeta-
analyses in non-diabetic subjects. RV analyses also confirmed findings in other studies,
whereas significant RV associations with CNOT2, HPN-AS1, and SIRPD appear to be
novel (q< 0.1).
Discussion. Here we present findings for the largest GWAS of lipid levels in people
with type 2 diabetes to date. We identified 17 statistically significant (p< 1× 10−8)
associations of CV with lipid levels in 11 genes or chromosomal regions, all of which
were previously identified in meta-analyses of mostly non-diabetic cohorts. We also
identified 13 associations in 11 genes based on RV, several of which represent novel
findings.
Subjects Bioinformatics, Genomics, Diabetes and Endocrinology, Translational Medicine,
Metabolic Sciences
Keywords Exome, Diabetes, Genetics, Lipids, Rare variants, Genomics
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INTRODUCTION
Cardiovascular diseases (CVD) remain the leading cause of deathworldwide (Mendis, Puska
& Norrving, 2011). Individuals with type 2 diabetes mellitus are at an increased risk of CVD
compared to individuals without type 2 diabetes (Malmberg et al., 2000). Approximately
65% of people with diabetes aged 18 years or older have increased low-density lipoprotein
(LDL) levels or use cholesterol-lowering medications, and are at a significantly increased
risk of CVD, stroke, and other adverse events (Centers for Disease Control and Prevention,
2014). Associations between plasma lipid concentrations and genetic markers are of great
interest because total cholesterol (TC), LDL, high-density lipoprotein cholesterol (HDL)
and triglycerides (TG) are heritable risk factors for cardiovascular disease (Kathiresan et
al., 2007; Vattikuti, Guo & Chow, 2012) and identification of the genes involved can lead
to novel insights into the biology of lipid regulation and its effects on cardiovascular risk.
Large-scale genome-wide association studies of plasma lipid levels have been conducted in
populations composed largely of non-diabetic subjects, and have identifiedmultiple genetic
variants that affect lipid levels, many of which also affect cardiovascular risk (Global Lipids
Genetics Consortium, 2013). However, given the altered hormonal and metabolic milieu in
individuals with type 2 diabetes as well as the high incidence of dyslipidemia in this group,
it is reasonable to ask whether the effects of known genetic risk factors are the same in
individuals with type 2 diabetes as in the general public, and/or whether additional, novel
factors may contribute to the heightened risk in this group. Identifying genetic variants
associated with differences in TC, TG, LDL, and HDL in people with type 2 diabetes may
increase our understanding of biological mechanisms involved in diabetic dyslipidemia
and may guide the development of more targeted therapies and ultimately lower the risk
of CVD in people with type 2 diabetes.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial was
designed to be the definitive clinical trial comparing the risks and benefits of treatment
strategies targeting normal glycemic levels, normal blood pressure and intensivelymanaging
dyslipidemia with combined statin-fenofibrate therapy versus strategies with standard
targets and approaches in patients with type 2 diabetes at high risk forCVD (Goff et al., 2007;
Buse, 2007) The clinical trial was conducted at clinical centers across the United States and
Canada, and enrolled 10,251 middle-aged and older participants following them for up to
eight years. No benefit on the combined CVD endpoint of time to event of first heart attack,
stroke or CVDmortality was evident for intensive glycemic, blood pressure or lipidmanage-
ment; furthermore there was an increase in mortality associated with targeting normal glu-
cose levels (Gerstein et al., 2007;Ginsberg et al., 2007;ACCORD Study Group, 2010a). Given
the known heritability of type 2 diabetes, hypertension and blood lipid levels, it is important
to ask whether genetic factorsmay prove useful in predicting which individuals will respond
positively to intensive treatment.
Here we test >8 million common genetic variants, defined as minor allele frequency
(MAF)≥ 3%, and rare genetic variants (MAF < 3%) covering 16,538 genes in 7,844 subjects
with type 2 diabetes. Although large-scale meta-analyses incorporating multiple cohorts
of both healthy subjects and subjects with a variety of cardiovascular andmetabolic diseases
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have already identified more than 150 loci affecting blood lipids (Teslovich et al., 2010;Wa-
terworth et al., 2010; Global Lipids Genetics Consortium, 2013; Liu et al., 2014), the analysis
presented here represents the largest analysis to date comprised entirely of individuals with
type 2 diabetes. The current study thus allows us to determine whether the overall constel-
lation of loci affecting blood lipid levels is broadly similar between individuals with type 2
diabetes at a high risk of CVD and the general population, and has the potential to identify
novel or known loci that have a larger effect on lipid levels in individuals with type 2 diabetes.
METHODS
Study population
The ACCORD trial (NCT00000620; https://clinicaltrials.gov/ct2/show/NCT00000620)
had a double 2 × 2 factorial design, consisting of 10,251 recruited subjects with type 2
diabetes mellitus and either a history of cardiovascular disease (CVD) or at least two known
risk factors for cardiovascular disease, such as documented atherosclerosis, albuminuria,
dyslipidemia, hypertension, smoking, or obesity (Buse, 2007). Subjects were randomized to
either intensive or standard glycemia treatment strategies (targeting HbA1c < 6.0 vs. HbA1c
between 7.0 and 7.9). A subset of 4,733 subjects were further randomized to intensive versus
standard blood pressure management (targeting systolic blood pressure of <120 mm
Hg versus <140), and the remaining 5,518 subjects were randomized to intensive
versus standard lipid management (fenofibrate versus placebo, with all subjects on
simvastatin) (ACCORD Study Group, 2010b). The age range for subjects with a history
of CVD was 40–79, and for those with no prior CVD history, 55–79. Body mass
index (BMI) was limited to a maximum of 45, and serum creatinine to 1.5 mg per deciliter.
Median length of follow-upwas 4.7 years, and the primary outcomewas the first occurrence
of nonfatal myocardial infarction or nonfatal stroke or death from cardiovascular causes.
Participants in ACCORD were given an option to provide a blood sample for future
genetic studies, and over 80% of participants agreed to do so. After genotyping and quality
control (see Supplemental Information 1) of DNA extracted from these samples, the popu-
lation for the current study included 7,844 subjects. A comparison of baseline characteristics
of this subset of ACCORD to the entire ACCORD patient population is given in Table 1.
The subjects included in the current study were similar to the overall ACCORD participants
regarding all baseline demographic and clinical factors, and in the use of lipid lowering
drugs prior to the trial. Phenotypes consisted of baseline measurements for TC (mg/dL),
LDL (mg/dL), HDL (mg/dL) and TG (mg/dL). Data for TC, LDL, HDL, and TG were
extracted from the publicly released data files and then log transformed as shown in Fig.
1 to meet parametric assumptions of the statistical models described below. The Protocol
Review Committee, appointed by the National Heart, Lung, and Blood Institute (NHLBI),
approved the study protocol. Each ACCORD participant provided written informed
consent using procedures reviewed and approved by each clinical site’s local institutional
review board and based on a template provided by the study group that was approved
and subsequently centrally monitored by the Coordinating Center and the NHLBI (IRB:
FWA00003429). The portion of the informed consent document describing the genetics
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Table 1 Baseline characteristics of patients.
Characteristic Cohort mean (95% CI) ACCORDmean (95% CI)
Baseline age 62.78 (62.64–62.92) 62.77 (62.64–62.89)
BMI 32.32 (32.2–32.44) 32.22 (32.12–32.33)
Years diabetic 10.84 (10.68–11.01) 10.8 (10.65–10.95)
FPG2 175.2 (174.02–176.38) 174.4 (173.36–175.44)
HbA1c3 8.28 (8.26–8.3) 8.28 (8.26–8.3)
SBP4 136.08 (135.71–136.44) 136.15 (135.83–136.47)
DBP5 74.74 (74.51–74.97) 74.71 (74.52–74.91)
TC 183.13 (182.25–184.02) 182.91 (182.13–183.69)
LDL 104.56 (103.83–105.28) 104.72 (104.08–105.36)
HDL 41.82 (41.57–42.07) 41.8 (41.58–42.01)
TG 187.31 (184.71–189.91) 185.5 (183.24–187.76)
Characteristic Cohort (%) ACCORD (%)
Intensive glycemia arm (%) 50.05 50.02
Intensive blood pressure arm (%) 22.76 23.04
Female (%) 39.30 38.55
White (%) 64.32 62.36
History of cardiovascular disease (%) 34.14 35.21
Niacin at baseline (%) 1.80 1.79
Cholesterol absorption inhibitor at baseline (%) 2.22 2.02
Statin at baseline (%) 62.94 63.41
Fibrate at baseline (%) 6.53 6.12
Bile acid sequestrant at baseline (%) 0.42 0.41
Other lipid medications at baseline (%) 2.22 2.19
Notes.
1Student’s t -test.
6Fisher’s exact test.
component of ACCORD uses the multilevel approach recommended by the NHLBI
(National Heart Institute et al., 1997).
Genotyping
DNA extracted from stored white blood cells from ACCORD subjects who consented to
genetic research were obtained from the ACCORD Central Laboratory at the University
of Washington. DNA were quantitated using PicoGreen, and 200 ng of each DNA was
aliquoted into 96-well plates. Three duplicate ACCORD samples and two DNAs from
HapMap trios (obtained from Coriell Cell Repositories, Camden, NJ) were included as
controls on each plate. Amplification, fragmentation, and hybridization of DNA to Axiom
Biobank 1 genotyping arrays (Affymetrix, Santa Clara, CA) were carried out using Axiom
Reagent Kits, and hybridization, ligation, washing, staining and scanning of the arrays were
carried out on the GeneTitan MC instrument (Affymetrix). Initial plate QC was performed
using Affymetrix Genotyping Console Software and genotype calling was done using
Affymetrix Power Tools (v1.15.0) with the Axiom GT1 algorithm, which is a modified
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Figure 1 Histograms of raw and log10 transformed baseline lipid levels Normal distributions com-
puted using the baseline means and standard deviations are overlaid. (A–E) depict measured values and
(E–H) depict log-transformed values.
version of the BRLMM-P algorithm that adapts generic prior cluster positions to the data
using an EM algorithm.
The Axiom Biobank Genotyping Array from Affymetrix includes ∼246,000 common
genetic variants selected to optimize genome-wide coverage for association in addition
to ∼335,000 variants focused on the coding portion of the genome, and including non-
synonymous, frameshift, indel and splice variants as well as other known loss-of-function
and disease causing mutations. Most of this second group of variants was identified by
exome sequencing in up to 26,000 individuals, and the majority of them are uncommon or
rare. Additional variants to cover known eQTLs and pharmacogenomics markers are also
included on the array. A total of 628,679 probes were genotyped. After genotype quality
control, genotypes were available for 583,613 variants, of which 89,212 weremonomorphic.
After imputation based on 1,000 genomes haplotype data, an additional 26,862,499 imputed
variants with an ‘‘info’’ metric > 0.5 were retained for association testing. The genotype
information is available in dbGaP (http://www.ncbi.nlm.nih.gov/dbgap).
Data processing
Quality control
Genotypes were subjected to rigorous quality control based on genotyping quality
metrics, duplicate concordance, Mendelian segregation (in HapMap trios included on the
genotyping plates), Hardy–Weinberg Equilibrium, and predicted gender (see Supplemental
Material). Cryptic relatedness was identified using KING (v1.4), and one member of each
pair with a kinship coefficient >
( 1
2
) 5
2 = 0.1768 was removed from the analysis data set
(random seed: 1,485) (Manichaikul et al., 2010). Principal components (PCs) based on
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Figure 2 First two principal components with markers indicating self-reported ethnic backgrounds.
the genotype data were computed using EIGENSTRAT (v4.2) and were used to control
population stratification (Price et al., 2006). The first two PCs are shown in Fig. 2, where
the marker colors and labels represent the self-reported ethnic background for each sample.
Genotype imputation was accomplished using a two-step approach where the genotype
calls were first pre-phased using SHAPEIT2 (v2.r778) and then imputation was conducted
using IMPUTE2 (v2.3.0) (Howie, Donnelly & Marchini, 2009; Howie, Marchini & Stephens,
2011; Delaneau, Marchini & Zagury, 2012; Delaneau, Zagury & Marchini, 2013). Both steps
used the 1,000 Genomes Phase1 integrated haplotypes reference panel (release date Dec
2013) from the IMPUTE2 website. Probes significantly deviating from HWE (χ2> 19.51,
p-value < 10−5) in at least two of the four main ethnic subgroups were excluded from the
imputation process. Values of the cleaned probe set for white samples are shown in Fig. S14.
All samples were pre-phased together since this approach was previously found to improve
phasing in a cohort with diverse ancestries compared to phasing groups separately
(Delaneau, Zagury & Marchini, 2013). The imputation process began by splitting the pre-
phased haplotype data into 5Mbp non-over-lapping segments for each chromosome, using
the same reference panel from the pre-phasing step. Only those variants with an ‘‘info’’
metric > 0.5 were retained for association testing, resulting in a total of 26,862,499
imputed variants (∼71.7% of total imputed variants). Additional information regarding
the pre-phasing and imputation process can be found in the File S1.
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Covariate selection
Here, we take a combined approach to variable selection to address potential confounding
variables. Some covariates are forced into the model based on the results of previous studies
or on expert knowledge related to the phenotype, while variable selection, via backwards
selection, is subsequently performed on candidate variables to identify covariates specific to
the ACCORDdataset. Covariate names and descriptions can be found in Tables S3 and S4. A
substantial proportion of the cohort was taking lipid loweringmedications at the time base-
line lipid measurments were taken (e.g., 63% were on a statin). Lipid lowering concomitant
medications were forced into the model to prevent confounding of the baseline lipid
measurements. The percentage of the cohort on each of these lipid lowering medications is
in Table 1 and additional information is in Table S3. Years since diabetes diagnosis and years
of hyperlipidemia diagnosis were mean imputed due to large numbers of patients missing
those records. Only samples with complete phenotype and covariate data were retained.
A correlation matrix for all covariates is shown in Fig. S18. Three pairs of covariates were
flagged for high correlation, and one of each pair was removed prior to analysis: glomerular
filtration rate and serum creatinine were negatively correlated (r =−0.77), systolic and
diastolic blood pressure were positively correlated (r = 0.53) and BMI and waist circum-
ference were positively correlated (r = 0.63). See Supplemental Material for additional
information regarding covariate selection.
Heritability approximation
Thephenotypic variation explained by genome-wide variants is estimated using the software
tool genome-wide complex trait analysis (GCTA; v1.22) (Yang et al., 2011). An estimate
of a phenotype’s heritability can help to determine if the results from association tests
seem plausible. Additional information regarding the heritability approximation is in the
Supplemental Material.
Common variant analysis
Association between a phenotype and single common variant is tested using the linear
regression model
y =α0+Xα+βg g+,
where y is the phenotype, α0 is the intercept, X are the covariates, α are the covariate
regression parameters, βg is the regression parameter for the variant, g is the additively
coded genotype and  is the error term. Genotyped variants are tested using PLINK, where
gi ∈ {0,1,2} is the number of minor alleles for the ith individual. Imputed variants are tested
using a linear regression model in the statistical programming language, R, where gi =
pi(Aa)+2pi(aa) is the dosage score computed from the posterior probabilities for genotypes
Aa and aa (R Development Core Team, 2014).
The resulting test statistics from the common variant analysis were adjusted for genomic
inflation (Devlin & Roeder, 1999). Genomic inflation values were used as a guide for
selecting the MAF threshold of 3% to separate common and rare variant analyses.
Additional information about the MAF selection criteria can be found in the Supplemental
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Material. The results from the common variant tests were considered statistically significant
based on a p< 1×10−8.
Rare variant analysis
Current approaches can be commonly divided into burden and non-burden approaches.
Burden tests collapse a set of rare variants from a region of interest (e.g., a gene) into a single
variable, which is then tested for association with a phenotype. However, a major limitation
of simple burden tests is that they cannot account for the possible direction (positive
or negative association) of a rare variant effect (Wu et al., 2011). One non-burden rare
variant test that allows for different directions and magnitudes of effects for each variant is
the sequence kernel association test (SKAT) (Wu et al., 2011). The approach used here is
to apply a suite of tests that are representative of commonly used methods in the literature
that cover both burden and non-burden approaches.
Simple collapsing methods use indicator, proportion and weighted approaches chosen
a priori that can easily be computed from genotype data. More sophisticated approaches
can incorporate variant-specific information and variable thresholds for collapsing. Three
burden tests are used here and are based on simple collapsing approaches. These methods
first create a collapse score, c , and then test for association using the linear regressionmodel
y =α0+Xα+βc c+,
where y is the phenotype, α0 is the intercept, X are covariates, α are the covariate regression
parameters, βc is the regression parameter for the collapse score and  is the error term.
Association p-values are computed under the null hypothesis H0 : βc = 0. The selected
burden tests differ in how c is computed.
The first two tests are based on RVT1 and RVT2 originally proposed byMorris & Zeggini
(2010). We adapted a slight change to RVT1 where ci=
(
6jgij
)
/2ni, which counts the total
number of rare alleles rather than the number of variants with rare alleles. In RVT2, ci is
simply an indicator function ci= I (ri> 0). The third test uses a weighting scheme similar
to the one proposed in the weighted sum statistic (WSS) case-control method (Madsen &
Browning, 2009). While burden tests use simple linear regression, SKAT uses a linear mixed
model and tests for association with a variance-component score test (Wu et al., 2011).
While SKAT has been found to be more powerful than burden tests when the variants
have different directions of effect, it is less powerful when all variant effects are in the same
direction. The balance between SKAT and burden tests was addressed by the optimal test,
SKAT-O, where a combination of the two approaches is optimized (Lee, Wu & Lin, 2012).
Additional information regarding the rare variant testing implemented here is in the
Supplemental Material.
Here we use both SKAT and SKAT-O in addition to the three burden tests mentioned
above. Only those variants <3% MAF were included in the rare variant approaches. The
non-burden approaches were implemented using the R package ‘‘SKAT’’ (v0.95) (Lee,
Miropolsky & Wu, 2013).
The use of multiple rare variant tests for each gene compounds the problem of multiple-
hypothesis testing. Application of a correction for multiple testing, such as a false discovery
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rate (FDR) (Storey, 2002) approach is not straightforward due to each gene having a set of
p values, one for each rare variant test. This complication can be resolved by combining
the set of p-values into a single p-value for each gene, while accounting for the dependence
of p-values using the ‘‘correlated Lancaster procedure’’ described by Dai et al. to combine
the p-values from each test into a single p-value for each gene (Dai, Leeder & Cui, 2014).
Combining the set of p-values for each rare variant test into a single p-value for each gene
allows straightforward application of FDR controlling procedures. Computing q-values was
done using the R package, q value (v1.36.0) (Dabney, Storey & Warnes, 2004). Additional
information about combining the rare-variant p-values is in the Supplemental Material.
RESULTS
After all sample quality control steps a total of 7,844 individuals were included
in the association analysis for TC (mg/dL), LDL (mg/dL), HDL (mg/dL) and TG
(mg/dL) phenotypes. Heritability for each phenotype was approximated using the
set of genotyped variants to construct the genetic relationship matrix (GRM). The
phenotype, pruned covariates and GRM were used by GCTA to compute an approximate
heritability of 11.7%, 11.3%, 43.7% and 14.0% for TC, LDL, HDL and TG, respectively.
Common variant analysis
All common genotyped and imputed variants were tested individually for association
using PLINK or a linear model in the statistical programing language, R, respectively. A
set of LD pruned (VIF < 1.5), genotyped probes was used to compute genomic inflation
values for different MAF thresholds, as shown in Fig. S20, and a MAF threshold of 3% was
subsequently selected. The inflation values at MAF = 3% are 1.00, 1.00, 1.02 and 1.00 for
TC, LDL, HDL and TG, respectively. A total of 292,816 genotyped and 7,812,348 imputed
variants had MAF > 3% and were included in the common variant analysis. Quantile–
quantile (QQ) plots for the common variants are shown in Fig. S21, along with lambda
values. The location of significantly associated loci can be seen on a Manhattan plot, where
the negative log transformed, genomic control adjusted p-values versus genomic location for
each of the phenotypes are shown in Figs. 3A–3D for TC, LDL, HDL, and TG, respectively.
Three peaks reaching genome-wide levels of statistical significance (p< 1×10−8) were
observed in the TC association. The lead markers in these regions are located 109.82 Mb
on Chr1, 126.5 Mb on Chr8, and 45.41 Mb on Chr 19 (Fig. 3A). These SNPs are located
in genes CELSR2, TRIB1, and APOE, respectively (Table 2). In the LDL common variant
analysis, two significant peaks were observed at 109.82 Mb on Chr1 and 45.41 Mb on Chr
19, located in CELSR2 and APOE genes, respectively (Fig. 3B and Table 2). Five peaks
represent statistically significant associations with HDL (Fig. 3C). The lead SNPs in these
peaks were located 19.82 Mb on Chr 8, 58.68 Mb on Chr 15, 56.99 Mb on Chr 16, 47.17
Mb on Chr 18, and 45.41 Mb on Chr 19, although the lead SNP in the peak on Chr 19
(rs429358) is not in HWE (p< 1×10−5) in all populations combined. These lead SNPs
are in the LPL, LIPC, CETP, LIPG, and APOE genes, respectively (Table 2). Lastly, seven
peaks were observed with SNPs significantly associated with TG levels. The lead SNPs
in these peaks are located 63.07 Mb on Chr1, 27.73 Mb on Chr 2, 73.02 Mb on Chr 7,
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Figure 3 Manhattan plots for common variant analysis Red line indicates significant p-values (p= 1× 10−8). (A) Total cholesterol, (B) low den-
sity lipoprotein, (C) high density lipoprotein, (D) triglycerides.
19.82 Mb and 125.58 Mb on Chr 8, 116.65 Mb on Chr 11, and 45.41Mb on Chr 19 (Fig.
3D). The SNP (rs6982502) on Chr 8 was significantly out of HWE (p< 1×10−5) in all
populations combined. These SNPs are located in the ANGPTL3, GCKR, MLXIPL, LPL,
TRIB1, ZNF259, and APOE genes, respectively (Table 2).
Rare variant analysis
All functional variants (annotated based on GRCh37p13 build and retained those with
accession numbers beginning with ‘‘NM’’ and having codes for stop-gain, missense,
stop-loss, frameshift, cds-indel, splice-3 and splice-5) and a MAF < 3% were considered
for incorporation into the gene-based, rare variant analysis. After QC, a total of 16,480
genes contained at least two variants below the MAF threshold. In total, 146,689 genotyped
and 73,295 imputed variants went into the analysis, with median of nine variants per gene.
Mean minor allele frequencies for all the rare variants in an individual gene ranged from
6.37e–05 to 2.53e–02. The suite of three burden and two nonburden tests were applied
and the resulting p-values were combined using the correlated Lancaster procedure, as
described above. QQ plots for each of the phenotypes are shown in Fig. 4, where the marker
colors indicate q-value significance thresholds.
A total of 11 genes were significantly associated with TC, LDL, HDL, or TG in the
combined rare variant analysis (q< 0.1), with the number of rare variants in these genes
ranging from two to 22 (Table 3). Variants in PCSK9 were associated with TC and LDL.
LPL, CNOT2, CETP, HNF1B, ANGPTL4, and HPN-AS1 were associated with HDL, and
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Table 2 Common variant genes of interest.
Locus Lead
marker
Chr GRCh37
pos. (Mb)
Associated
trait(s)a
Major/minor
allele
MAF Beta
sign
p-value HWE
p-value
ANGPTL3 rs67461605 1 63.07 TG GTTAATGTG/- 0.34 – 2× 10−13 0.1641
CELSR2 rs7528419 1 109.82 LDL, TC A/G 0.23 – 6× 10−17 0.3715
GCKR rs1260326 2 27.73 TG C/T 0.34 + 1× 10−9 3.70E–05
MLXIPL rs13240065 7 73.02 TG G/A 0.11 – 2× 10−12 0.1131
LPL rs15285 8 19.82 HDL C/T 0.32 + 5× 10−24 0.000496
rs75278536 19.82 TG T/G 0.09 – 1× 10−17 0.1483
TRIB1 rs28601761 8 126.5 TC C/G 0.38 – 2× 10−9 0.2015
rs6982502 125.48 TG T/C 0.41 – 1× 10−8 3.74E–09
ZNF259 rs964184 11 116.65 TG C/G 0.16 + 3× 10−24 0.1834
LIPC rs1532085 15 58.68 HDL G/A 0.4 + 6× 10−10 0.003875
CETP rs247617 16 56.99 HDL C/A 0.3 + 2× 10−43 1
LIPG rs4939884 18 47.17 HDL C/T 0.14 – 2× 10−9 0.2113
APOE rs7412 19 45.41 LDL, TC C/T 0.08 – 8× 10−44 0.677
rs75627662 45.41 TG C/T 0.18 + 4× 10−13 0.1244
rs429358 45.41 HDL T/C 0.14 – 9× 10−10 6.34E–06
Notes.
Chr, chromosome; MAF, minor allele frequency; TC, total cholesterol; TG, triglycerides.
aPrimary trait listed first.
APOC3, PAFAH1B2, ANGPTL4, SIRPD, and UBE2L3 were significantly associated with
TG (Table 3).
DISCUSSION
Associations between lipid plasma concentrations and genetic variants have been of great
interest because TC, LDL, HDL and TG are heritable risk factors for cardiovascular disease.
Previous meta-analyses of genetic association studies involving multiple epidemiological
and case-control cohorts have been conducted to identify genetic variants associated with
specific lipid concentrations, but here we provide an analysis focused on genetic variants in
a large cohort of subjects with type 2 diabetes and a high risk of CVD. Furthermore,
we identify genes with rare variants (MAF < 3%) significantly associated with lipid
concentrations.
Several large meta-analyses have previously investigated genetic variants associated with
lipid levels. For example, Teslovich et al. (2010) conducted a meta-analysis combining 46
genome-wide association studies (GWASs) for TC, LDL, HDL, and TG . This study tested
variants with a MAF > 1% for associations with lipid levels in ∼100,000 individuals of
European ancestry. Approximately 2.6 million SNPs, were tested for association with each
of the four lipid traits in each study, and 95 significant loci (p < 5 × 10−8) were found,
which included all 36 loci previously reported in GWASs at the time and 59 novel loci. An
expanded study was performed on ∼189,000 individuals, primarily of European ancestry,
in a 2013 meta-analysis conducted by Global Lipids Genetics Consortium (2013). Using this
larger cohort, 157 loci associated with lipid concentrations were identified, 62 of which
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Figure 4 Rare variant quantile–quantile plots.Quantile–quantile plots are shown for (A) TC (B) LDL
(C) HDL (D) TG. Color indicates q-value threshold.
were novel. A comparison of the ACCORD results with all of the significant results from
the Global Lipids Genetics Consortium can be found in File S1. Approximately 30% the
loci yielding genome-wide significant levels of association with TC and LDL in the Global
Lipids Genetics Consortium analysis and 35% of the loci similarly associated with HDL
and TG yielded at least nominally significant levels of association (p < 0.05) with the same
phenotypes in ACCORD.
Some cohorts included in these and other large-scale meta-analyses included subjects
with type 2 diabetes, but these only represent a small proportion of the overall subjects
studied. One early GWAS comprised of approximately half individuals with type 2 diabetes
and halfmatched controls fromFinland and Sweden tested associations with LDL,HDL and
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Table 3 Rare variant genes of interest.
Genea Chr Associated trait(s)b Number of variantsc p-value q-value
PCSK9 1 LDL, HDL 22 (12) 4× 10−11 1× 10−7
LPL 8 HDL 16 (15) 3× 10−5 0.0301
APOC3 11 TG 2 (1) 3× 10−7 0.0018
PAFAH1B2 11 TG 3 (1) 7× 10−5 0.0775
CNOT2 12 HDL 2 (2) 2× 10−5 0.0283
CETP 16 HDL 18 (14) 4× 10−7 0.0014
HNF1B 17 HDL 5 (3) 1× 10−4 0.0848
ANGPTL4 19 TG, HDL 14 (12) 2× 10−6 0.0049
HPN-AS1 19 HDL 2 (2) 1× 10−4 0.0915
SIRPD 20 TG 5 (3) 8× 10−5 0.0775
UBE2L3 22 TG 2 (0) 4× 10−5 0.0636
Notes.
Chr, chromosome; TC, total cholesterol; TG, triglycerides.
aBold indicates potentially novel gene association.
bPrimary trait listed first.
cTotal number of variants (# of genotyped variants).
TG in∼2,600 subjects (Diabetes Genetics Initiative of Broad Institute of Harvard and MIT et
al., 2007). Associations at genome-wide significant levels were found at common variants in
APOE (with LDL), CETP (HDL), andGCKR (TG), and associations at suggestive levels were
found in APOB (LDL), LPL (HDL and TG), LIPC (HDL), and APOA5 (TG). All of these
genes were either known at the time to influence lipid levels or subsequently corroborated
by the large GWAS meta-analyses, and all of these associations with the exception of ApoB
were also found, at genome-wide significant levels, in the present study. Interestingly,
previously reported heritability estimates for LDL, HDL, TC, and TG have approximated
25–70% (Kathiresan et al., 2007; Vattikuti, Guo & Chow, 2012) , whereas, we report lower
heritability estimates, which may be due to the incorporation of different covariates in the
present analysis.
The common variant GWAS results presented here for lipid levels in subjects at the
baseline visit of the ACCORD trial are summarized in Table 2. The leadmarker corresponds
to the variant with the smallest p-value for each peak on the corresponding Manhattan plot
(Figs. 3A–3D). The locus corresponding to each lead marker is either the gene in which the
marker is located or the closest gene. Some markers are associated with multiple traits,
in which case the p-value corresponds to the primary trait. All of these genes or adjacent
chromosomal regions were reported in either the Teslovich et al. or Global Lipids Genetics
Consortiummeta-analyses described above. Amarker nearCELSR2was previously reported
by Teslovich et al. (2010), but its effects were ascribed to the SORT1 gene. CELSR2 is part
of the CELSR2-PSRC1-SORT1 gene cluster, and was previously associated with coronary
artery disease and circulating lipid levels (Waterworth et al., 2010; Arvind et al., 2014).
Small interfering RNA knockdown of Sort1 in the mouse was shown to alter plasma LDL,
indicating that this is likely the causal gene in this gene cluster (Musunuru et al., 2010).
ZNF259 is adjacent to APOA5, APOA4, APOC3, APOA1, and BUD13, all of which have
been previously associated with differences in circulating plasma lipids (Pollin et al., 2008;
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Teslovich et al., 2010; Ota et al., 2011; Global Lipids Genetics Consortium, 2013; Aung et al.,
2014). These genes are in high linkage disequilibrium, and although functional studies have
demonstrated a clear role for apolipoprotein genes in regulating lipids (Ito et al., 1990;Rubin
et al., 1991; Pennacchio & Rubin, 2003), additional studies are needed to fully understand
how these genes influence disease. The results presented here contribute additional vali-
dation to previously reported associations, while also indicating that the common genetic
variant profiles associated with lipid levels are similar between individuals with and
without type 2 diabetes, although individuals with type 2 diabetes are at increased risk of
cardiovascular disease and dyslipidemia.
Missing heritability unaccounted for by traditional GWAS employing common variants
has motivated the investigation of rare variants (Manolio et al., 2009). A traditional single-
locus analysis approach applied to rare variants suffers from low power and a wide range
of approaches that combine multiple rare variants into single tests are now available to
address this problem (Bansal et al., 2010; Dering et al., 2011; Lee et al., 2014). Because each
method has advantages and limitations, the approach implemented here applies a suite of
tests that are representative of some of the more commonly used methods in the literature
and span both burden and non-burden approaches. Table 3 summarizes the findings of our
baseline lipid rare variant analysis. Proprotein convertase subtilisin kexin 9 (PCSK9) was
the only gene found to be associated with LDL in the rare variant analysis, and associations
with this gene and LDL levels have been previously reported in Lange et al. (2014) and a
meta-analysis conducted by Liu et al. (2014). Interestingly, development of drugs targeting
PCSK9 to lower LDL have been a high priority in the pharmaceutical industry, and based
on promising results in clinical trials, the first drug targeting PCSK9 (Evolocumab) was
recently recommended for expedited approval by the US Food and Drug Administration
(Koren et al., 2014; Stroes et al., 2014; United States Food and Drug Administration, 2015).
This demonstrates the tremendous potential of these types of analyses, and the results here
suggest that drugs targeting PCSK9 may also be relevant for lowering LDL in individuals
with type 2 diabetes. Additionally, Liu et al. (2014) found significant associations based on
rare variants in the LPL and ANGPTL4 genes, further supporting the findings presented
here. UBE2L3 was associated with HDL in the common variant, meta-analysis by Teslovich
et al. (2010), but our rare variant results demonstrate an association with TG as well. Peloso
et al. conducted a mega-analysis of 13 studies for a total of ∼56,000 individuals, 42,000
of European ancestry (EA) and 14,000 of African ancestry (AA), which investigated the
association of low-frequency and rare coding variants with LDL, HDL and TG (Peloso
et al., 2014). Gene-based rare variant associations were found for APOC3 and CETP,
which we replicated here (Table 3). Peloso et al. (2014) also found a low-frequency variant
association for PAFAH1B2 with HDL and TG, which supports our rare variant association
of PAFAH1B2 with TG.
The individuals in the ACCORD trial have type 2 diabetes and are also at a high risk of
CVD; however, many of the significant associations observed here have been previously
reported in the literature, indicating that many of the genetic contributions to dyslipidemia
are similar between these individuals and individuals without type 2 diabetes. In contrast,
the rare-variant analysis produced four significantly associated genes that, to our knowledge,
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Figure 5 Boxplots of log10 phenotype versus genotype. Boxplots are shown for genes (A) CNOT2, (B) HNF1B, (C) HPN-AS1, (D) SIRPD, (E)
PAFAH1B2, and (F) UBE2L3. The boxplots are color coded for each variant and the number of samples for each genotype are indicated below the
allele labels. Genotyped variants are indicated by an asterisk following the rsID. The width of the bars is proportional to the number of subjects in
each group.
have not been previously reported for either HDL or TG. Figure 5 contains boxplots of
the log10 phenotype values versus genotype for the novel rare variant genes. The majority
of the functional variants are missense. The only exceptions to this are rs145641015 and
rs150515110 in SIRPD, which are both STOP-GAIN variants. HPN-AS1 is an antisense
RNA gene overlapping the HPN gene, and the annotations related to protein function
Marvel et al. (2017), PeerJ, DOI 10.7717/peerj.3187 15/23
on which variants were selected for inclusion in the gene-based analysis were actually for
HPN, so their relevance to HPN-AS1 are unclear. Little is known about the function of
genes CNOT2, HPN-AS1, and SIRPD and their relation to lipid regulation, and additional
follow-up studies will be necessary to better understand their role in regulating lipid levels.
Interestingly, hepatocyte nuclear factor 1 homeobox B (HNF1B) was significantly associated
with an increase in HDL (q= 0.085). HNF1B encodes the transcription factor (HNF1B)
that regulates a wide range of target genes and is involved in several pathologies including
cancer, renal cysts and diabetes syndrome, an early onset form of diabetes (HNF1B-
MODY), impaired glucose metabolism, venous thrombosis, and several others (Kornfeld
et al., 2013; Cuff et al., 2013; Kanthimathi et al., 2015; Raaijmakers et al., 2015). However,
this association was driven largely by rs8068014, which was heterozygous in 238 subjects,
201 of whom are black, and homozygous for the variant allele in nine subjects, seven of
whom are black. When this analysis was run only on black subjects the association with
HNF1B was no longer statistically significant (q > 0.1). HDL is higher in blacks than
whites overall, so despite efforts to control for population stratification by incorporating
PCs as covariates in the analysis, it appears that the apparent association of HNF1B with
HDL levels in all subjects combined may be due to confounding by population admixture.
Additional research is needed to better understand the role of HNF1B and the other novel
associations presented here. Although many genetic associations presented here are similar
to previous findings in cohorts not focused on diabetes, these findings shed new light on
the relationship of dyslipidemia in both individuals with and without type 2 diabetes and
the novel findings presented here may indicate new biomarkers or therapeutic targets to
better regulate alterations in lipid levels in high-risk, populations with type 2 diabetes.
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